Semaglutide vs Cagrilintide

Overview

This comparison separates Semaglutide and Cagrilintide for reference—not product selection.

Semaglutide: GLP-1 receptor agonist approved for type 2 diabetes and weight management; the most studied compound in its class.

Cagrilintide: Long-acting amylin analogue studied on its own and combined with semaglutide in obesity trials.

Differences

• Semaglutide is discussed in relation to GLP-1 receptor; Cagrilintide is discussed in relation to calcitonin receptor.
• Both appear in Metabolic & GLP-1 research literature, but mechanistic framing differs.

Mechanism

Semaglutide: Semaglutide activates the GLP-1 receptor. In plain terms it extends and amplifies the signal your body normally sends after a meal: the stomach empties more slo…

Cagrilintide: Amylin is released with insulin after eating and contributes to feeling full. Cagrilintide acts on the same receptors — the amylin and calcitonin receptors — bu…

Pharmacology

Semaglutide: Pharmacokinetic detail should be read from primary literature.

Cagrilintide: Pharmacokinetic detail should be read from primary literature.

Research

Semaglutide: Metabolic & GLP-1 research: FDA-approved for chronic weight management with average 15-20% body weight loss in clinical trials.

Cagrilintide: Metabolic & GLP-1 research: Phase 3 trials demonstrate significant weight loss.

Summary

Distinction

• AXIOM does not provide dosing, administration, or protocol guidance.
• Catalogue links appear only where AXIOM lists a research-use product.
• Reference-only compounds remain comparison terms without implying availability.

References

• pubmed.ncbi.nlm.nih.gov/40305708/
• pubmed.ncbi.nlm.nih.gov/33567185/
• pubmed.ncbi.nlm.nih.gov/37952131/
• pubmed.ncbi.nlm.nih.gov/31185157/
• pubmed.ncbi.nlm.nih.gov/37622681/
• pubmed.ncbi.nlm.nih.gov/36322838/
• pubmed.ncbi.nlm.nih.gov/27633186/
• pubmed.ncbi.nlm.nih.gov/36216945/

Questions